free skin, this variety of melanoma may arise in association with a melanocytic navus of junctional, compound or intradermal type, though the latter case seems to be uncommon. The practical problem is often that of recognizing malignant melanoma in association with a pre-existing nwvus; I say 'in association with' rather than 'malignant change in' because it is by no means proven that the nwvus provides other than a focus of unstable skin in which melanoma develops. Transformation of nevus cells to melanoma cells has not been demonstrated.
Lastly, I refer to a group of melanomas which is a subdivision of the second group. These patients present with either partial or total regression of their melanoma and, in my experience, invariably with regional lymph node metastases. Indeed, the commonest mode of presentation of this spontaneously regressing group is with the regional lymph node enlargement and only deliberate questioning about a pre-existing skin blemish which had undergone a period of growth, darkening, ulceration and then partial or total disappearance will lead to the discovery in the lymphatic territory, which the nodes drain, of a blanched or poorly pigmented area, the site of the original melanoma, which may be verified in the excised specimen. A curious variant is the halo melanoma, the malignant counterpart of the halo nevus. This is a condition in which spontaneous regression is associated with a vitiliginous zone around a central pigmented area.
From the standpoint of therapeutics, the melanocytic tumours in the skin may be considered in the following groups: (1) Benign lesions which rarely undergo a malignant changethe melanocytic nevi with nevus cells of junctional, compound, dermal or juvenile (Spitz) type, or the balloon cell variant. (2) Benign lesions which may be misinterpreted as malignant, for example the benign metastasizing blue nevus and the curious case of neevus cell deposits in lymph nodes.
(3) The group of nevi which often undergo malignant change, namely the bathing trunk nwvus. (4) The group I refer to as chronic malignant melanoma or melanoma lente, comprising the Hutchinson freckle, which is a biological type of in situ melanoma, the infiltrating melanoma arising in the Hutchinson freckle, and also some types of malignant blue nmvus. (5) The ordinary malignant melanoma. (6) The group of cases which present with metastases from a malignant melanoma following elimination of the primary tumour therapeutically or by spontaneous regression.
The morphology and behaviour of cutaneous tumours derived from the melanocyte are summarized in Table 1. Mr J M Edwards (Surgical Unit, St Thomas's Hospital, London SEJ) 
Malignant Melanoma: Surgical Aspects of Treatment
The treatment of malignant melanoma has created as much discussion as that argument concerning the origin of the melanoblast itself. It is now largely agreed that the melanoblast arises from neuroectoderm, this assumption being reinforced especially by the work of Masson (1948) . Malignant melanoma is the tumour arising from the melanoblast. There is also more or less universal agreement on how the primary lesion should be dealt with; further than that there is a good deal of controversy, especially on management of the regional lymph nodes.
Treatment ofthe Primary Melanoma
Most clinicians agree on the initial treatment of the primary tumour. This must be surgical, although some surgeons combine this stage with chemotherapy given regionally or systemically.
An excision biopsy is done if there is doubt concerning the clinical diagnosis and especially if the lesion is situated, for example, on the face where the result of a definitive wider excision with skin grafting would be unacceptable for a benign tumour. The biopsy must encompass the suspected lesion completely with a clear margin of normal skin around the edges of the tumour. An urgent paraffin section report is usually available after 24-48 hours and, should the lesion prove to be invasive malignant melanoma, then a further wider excision is necessary.
Most lesions are diagnosed initially as malignant melanoma and treated as such with a wide excision necessitating skin grafting. Special precautions are taken not to touch the melanoma during the operation, and the wound is carefully irrigated with distilled water or Clorpactin prior to the placement of a skin graft. The graft is always taken as the first separate procedure from the donor site on the contralateral limb.
There are two debatable points when discussing management of the primary melanoma. First, how extensive an excision is necessary? It is impossible to be dogmatic on the actual dimensions of a wide excision. Some surgeons have mentioned certain dimensions, e.g. Bodenham (1968) suggests an excision with 5 cm clear margin in all directions from the edges of the tumour. In 1968 I suggested an average excision of 15 x 10 cm for the limb and trunk with the long axis in the direction of the lymph flow (Edwards 1969) , but this is only meant as a guide. With large tumours even wider excisions may be made and in certain situations, such as on the face, smaller areas tend to be excised. The defect nearly always needs covering with a skin graft. The objective of surgery is to encompass the tumour completely allowing for the possibility of local spread by permeation of intradermal lymphatics. One cause of recurrence, but not the most common, is cutting across permeated lymphatics. Probably the most common cause is actual tumour implantation into the wound or else retrograde reflux of lymph and tumour cells after cutting across lymphatics. There are various other theories for local recurrence in relation to the primary excision but they are less convincing. The dimensions I have quoted were based on intradermal dye studies, noting the extension of a dye through intradermal plexuses, but of course the analogy with tumour permeation is not accurate.
The second point of debate is whether to remove deep fascia or not during the excision procedure. I believe that the deep fascia should be left intact and this belief is especially endorsed by Olsen (1964) who found definite disadvantage in removing this antomical barrier.
Further discussion on the treatment of malignant melanoma must entail consideration of how the lesion may be spread. There are three methods of spread. The first is by direct extension (see above). The second route, by lymphatic dissemination, is of extreme importance, and its management causes controversy. Tumour cells may spread to the regional lymph nodes as emboli via the subcutaneous lymphatic vessels. In the dermal lymphatics the tumour tends to spread by direct permeation. Thirdly, bloodstream spread usually occurs as a late feature, often after signs of involvement of regional lymph nodes. It may, however, occur early. Passage of tumour cells into the bloodstream can occur directly, from the primary site, from tumourinvolved lymph nodes via lymphovenous shunts, or after passage through the thoracic duct.
The staging of melanoma correlates with evidence of tumour dissemination. Stage I: primary melanoma, regional nodes clinically negative. Stage II: primary melanoma, regional nodes clinically positive. Stage III: primary melanoma, skin metastases in anatomical area outside the limits of a normal excision. Stage IV: disseminated disease. The management of Stage Ill and IV disease will not be dealt with in this discourse owing to the wholly different nature of the disease in these stages, which merits separate detailed discussion.
Treatment ofStage I Melanoma If the regional nodes appear clinically uninvolved although histological examination of such excised nodes shows tumour spread in at least one-third of cases, then there are various courses of action.
Probably the commonest policy adopted by surgeons in Great Britain is a policy of 'wait and see' following excision of the melanoma, especially if the site of the melanoma is at some distance from the regional node area. Should nodes subsequently enlarge, then a 'block dissection' is done at that time. If the primary lesion is situated close to the lymph node area then a monobloc dissection of tumour plus lymph nodes is often performed. Node dissections in discontinuity with the melanoma are avoided by these surgeons for Stage I disease because of the high incidence of skin metastases in the intervening skin and also because in a large proportion of patients normal lymph nodes are removed which may have an important role in combating the spread of disease.
Other surgeons, however, would rather not let small metastases in nodes enlarge to produce obvious disease. At that stage they believe that valuable time has been lost and the patient left in a parlous state. Consequently a prophylactic node dissection is performed removing lymph nodes which show metastatic spread in various proportions depending on how diligently they are looked for in the microscopical sections. Fortner et al. (1964) found that in 38-2% of their Stage I patients, lymph node involvement was demonstrated in the excised specimens.
Endolymphatic therapy: The policy in the Surgical Unit at St Thomas's Hospital is to give prophylactic treatment for these patients in the nature of endolymphatic therapy to the regional nodes. By this means lymph nodes containing small metastases can be destroyed but yet without cutting across lymph vessels and causing acute lymphatic obstruction in a limb. We have treated over 150 patients by these methods.
The primary melanoma is widely excised observing the principles already mentioned. After an interval of two to three weeks a direct injection of radioactive 32P-lipiodol (maximum dosage: 6-7 mCi in up to 4 ml ilio-inguinal, 3-4 mCi in up to 2 ml brachial) is made into lymphatics draining the site of the primary melanoma. This interval of time is necessary from several aspects. First, to be sure that the melanoma is truly an invasive malignant melanoma of the type that is likely to metastasize to lymph nodes and not a melanomain-situ or anomalous type that does well with primary excision alone. These types are occasionally included in some series which give false comparisons with other methods of treatment. A careful study is needed by an experienced pathologist to determine the nature of the lesion. Time is also needed to order the isotope combina- Again, there may be merit in delaying treatment to the lymph nodes assuming that there may be tumour cells in transit and consequently an interval is allowed for the regional nodes to filter off these cells.
The isotope combination that has been mainly used over the last five years is radioactive phosphorus (32P) in ultrafluid lipiodol. The technique of lymphography with radioactive materials has been described previously (Edwards & Kinmonth 1968 ). The main modifications of the methods originally described by Kinmonth et al. 1955a, b) have been concerned with safety factors due to the use of radioactive materials, and also with technique in the treatment of the regional lymph nodes. It is important to treat regional nodes that are directly involved in the lymph drainage of the primary melanoma and consequently injecttions are always made proximal to this area (Fig 1) . In addition, on occasions injections are made from multiple sites in order to cover as wide a regional node area as possible ( Fig IA) .
Great care is taken to give just sufficient radioactive material to fill the regional lymph nodes and no more. Thus radiographic control is exacting during the procedure in order to prevent excessive spillover to the lung fields. With conti-nuous monitoring of the infusion and stopping the injection after filling of the proximal lymph K / nodes, the spillover to the lung areas is usually less than 5 % of the total administered dose. This is a small percentage and there has been no (q & complication from this aspect. Subsequent to the procedure, which is usuallyperformed under general anesthesia, the patient with Stage I disease remains in hospital for five days, mainly for safety reasons. During this time urine is collected and blood samples are examined for leukocyte estimations. Previously, the radiation levels in blood and urine were estimated, but these proved to be so low and at such constant levels that they are not now done routinely. Further radiographs are taken twenty-four hours after the procedure in order to examine the lymph nodes more minutely (lymphadenograms).
In these films the nodes appear normal or may show filling defects suggestive of metastases ,#J larger than suspected. Usually in clinical Stage I disease there are no obvious filling defects and the patient can be released from hospital after a body C scan, using the Picker magnascanner. On   Fig 2 32P -lymphadenogram 24 hours after the infusionin patient ofheavy build in whom it was difficult to assess the condition ofthe regional nodes by palpation. She had aprimary melanoma ofthe lower leg which had been excised. Filling defects reveal metastatic involvement ofat least two lymph nodes in the inguinal group. Thepresence ofthe contrast material in lymphatics 24 hours after the infusion is also abnormal' showingpartial blockage oflymphflow occasion, filling defects show up in nodes which have been assessed as clinically uninvolved or else could not be palpated due to the body build of the patient (Fig 2) . Obvious lymph node disease requires surgical excision for complete eradication. The patient is followed up in the outpatient department initially at monthly intervals, when further clinical and radiological assessment of the lymph node condition is made (Fig 3) .
Treatment ofMelanoma Stage HI Disease
It is universally recognized that this stage represents a much more serious problem than Stage I disease. When the regional nodes are obviously involved then the prognosis is very much worse. The only possible treatment is to excise these nodes as a block dissection after treatment of the primary melanoma. Whenever possible this surgery should be performed in continuity as a monobloc excision.
Our policy is to precede the excisional surgery of the lymph nodes by intralymphatic infusion of 32P-lipiodol, as previously described, then allowing a period for the isotope to act and then decay to a safe level for surgery. This treatment policy is summarized as follows: (1) Wide excision of primary lesion. (2) Endolymphatic 32P-lipiodol to regional lymph nodes. (3) Block dissection of regional nodes six weeks following endolymphatic therapy. It is necessary to excise obviously involved lymph nodes even after endolymphatic therapy, as the range of penetration of the isotope used (32p) is not sufficient completely to destroy these nodes. The size of the metastases is too great (Fig 4) . The block dissection performed includes these nodes and also normal nodes above this level. The completeness of the dissection can be checked by means of radiographs taken during the operation (Fig 5) .
The advantages of combining endolymphatic therapy with surgery for Stage II disease may be summarized as follows: (1) It reduces the implantation of viable cells at operation site. (2) It extends the effective limit of treatment by treating proximal lymph nodes. (3) It provides operative radiographic aid to complete block dissection. (4) It gives diagnostic information for occult disease.
Results
One hundred and fifty-three patients with Stage I and II melanoma have been treated in the surgical unit at St Thomas's Hospital with surgery and endolymphatic therapy for periods of 1-12 years.
The first isotope used was radioactive colloidal gold (GLS1 P) and the first patient with melanoma was treated in 1958. A small series of 13 patients was treated by endolymphatic therapy using this isotope (Jantet et al. 1964) . The promising results of this study prompted further work on endolymphatic therapy, and other colloidal agents such as radioactive 90Y (2 patients in this series) have been used. The trend, however, has been towards the radio-opaque combinations such as 131Ilipiodol and 82P-lipiodol (78 and 66 patients respectively in this series).
As already mentioned, the advantages of radio-opacification of the lymph nodes are concerned with diagnosis and particularly with safety during procedure. Larger groups of The crude survival rate in this group of patients has been 74 % (39 deaths). For Stage I disease the survival rate over the entire period studied is 89-4%. Stage II disease presents a more serious prognosis with a crude survival rate of 47-3%. A group of 73 has been followed up for 5 years or more from the time of endolymphatic therapy. These patients represent the early treatment group when the isotopes used were principally radioactive gold 198Au or 1311. The five-year survival rate is 80 % for Stage I disease and 20 % for Stage II disease. It is hoped that these Stage IL figures will have improved with the increased use of 32P-lipiodol. However, even when analysing the results of 13ll-lipiodol in Stage II disease it is realized that the bad results are not due to ineffectiveness in treating the localized disease in lymph nodes. This was successful but patients died from systemic disease which must have been occult at the time of the initial treatment. In other words, the disease was already a systemic problem at the time of treatment.
Dr G A Currie (Chester Beatty Research Institute, Belmont, Sutton, Surrey)
Effect ofAutoimmunization with Irradiated Tumour Cells on Specific Cell-mediated Immunity in Patients with Malignant Melanoma
Recent progress in the study of animal tumours has encouraged us to re-examine the possibilities of using immunological methods in the treatment of cancer. The possible value of autologous tumour cell vaccines as a form of specific active immunotherapy was first tested over 70 years ago and has been the subject of many clinical investigations in the intervening years (for review, see Southam 1961) . In all these series of patients, treated with a variety of immunization techniques, there has been no evidence of any beneficial clinical effects. However, all the patients so treated were suffering from advanced malignant disease. We now know that a vigorous
